Overview

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This clinical trial is studying the side effects and best dose of zoledronic acid when given together with combination chemotherapy in treating patients with newly diagnosed metastatic osteosarcoma.
Phase:
Phase 1
Details
Lead Sponsor:
Children's Oncology Group
Collaborator:
National Cancer Institute (NCI)
Treatments:
Calcium, Dietary
Cisplatin
Dexrazoxane
Diphosphonates
Doxorubicin
Etoposide
Etoposide phosphate
Ifosfamide
Imidazole
Isophosphamide mustard
Lenograstim
Leucovorin
Levoleucovorin
Liposomal doxorubicin
Mesna
Methotrexate
Razoxane
Zoledronic Acid